Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Adenovir Pharma AB
TFS Trial Form Support AB
Information provided by (Responsible Party):
Adenovir Pharma AB Identifier:
First received: October 31, 2013
Last updated: April 30, 2015
Last verified: November 2013
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC. The aims of the study are to investigate the therapeutic efficacy of APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical resolution of EKC (objective and subjective assessments), presence of opacities, visual acuity and frequency of second eye infections, and to assess the safety and tolerability of APD-209 Eye drops in EKC infected eyes.

Condition Intervention Phase
Viral Conjunctivitis
Drug: APD-209 Eye drops
Drug: APD-209 Placebo Eye drops
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study

Resource links provided by NLM:

Further study details as provided by Adenovir Pharma AB:

Primary Outcome Measures:
  • The primary objective is to assess the adenoviral load in epidemic keratokonjunctivitis (EKC) infected eyes following topical treatment with APD-209 Eye drops compared to placebo. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Viral load in tear liquid from EKC infected eyes, as measured by the area under the curve (AUC) at 3-14 days from start of treatment.

Secondary Outcome Measures:
  • Assess the time to viral eradication in EKC infected eyes following treatment with APD-209 Eye drops compared to placebo. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    The time point of viral eradication in tear liquid from EKC infected eyes, defined as the time Point when viral load=0 or below the lower limit of quantification (LLOQ).

  • Evaluate the effect of APD-209 Eye drops on clinical resolution of EKC, as measured by objective and subjective assessment of scaled clinical symptoms, compared to placebo. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Resolution of acute ocular symptoms at each time of assessment, as measured by objective (Investigator-based) assessment of conjunctival discharge and redness.

  • Evaluate the presence of opacities (quantitatively and qualitatively) following treatment with APD-209 Eye drops compared to placebo. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Presence and location of opacities at each time of assessment, as measured by slit lamp examination.

  • Assess the visual acuity following treatment with APD-209 Eye drops compared to placebo. [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Visual acuity at each time of assessment by use of the logarithm of the Minimum Angle of Resolution (LogMAR) chart.

  • Assess the frequency of second eye infections. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Occurrence of second eye infection.

  • Assess the safety and tolerability of APD-209 Eye drops. [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
    Safety variables: adverse events (AEs) (nature and incidence), Physical examination, vital signs, laboratory safety assessments (haematology, clinical chemistry and urinalysis)

Estimated Enrollment: 130
Study Start Date: November 2013
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: APD-209 Eye drops
APD-209 Eye drops
Drug: APD-209 Eye drops
Placebo Comparator: APD-209 Placebo Eye drops
APD-209 Placebo Eye drops
Drug: APD-209 Placebo Eye drops


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

The patients have to meet all of the following criteria to be eligible to enter the study:

  • Willing and able to provide informed consent.
  • Men or women aged 18 to 65 years (inclusive) with onset of adenoviral EKC symptoms in at least one eye, as clinically diagnosed and with symptoms appearing within less than 72 hours at the time of giving informed consent.
  • Using adequate contraceptive measures

Exclusion Criteria:

  • Known or suspected allergy to any ingredient of the IMP or placebo.
  • Symptoms correlating with EKC since more than 48 hours.
  • Diagnosis of other significant disease(s) than EKC in the eye.
  • Diagnosis of bacterial or fungal ocular infections.
  • Use of antibiotics or corticosteroids by any route (except intravitreal corticosteroids) within 14 days prior to inclusion.
  • Use of immunosuppressive medications (including intravitreal corticosteroids) within 6 months prior to inclusion.
  • Use of antiviral medications within 7 days prior to inclusion.
  • Usage of any medication or herbal medicinal product with documented adverse reactions affecting the eyes.
  • Usage of any medication or herbal medicinal product for ocular administration at inclusion.
  • Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study period.
  • Known or suspected drug abuse.
  • Usage of contact lenses during the study.
  • Participation in any other interventional clinical study within 30 days prior to inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01977443

Contact: Björn Dellgren, M.Sc. +46 (0)42 38 74 28
Contact: Anita Westin Tocaj, Ph.D. M.Sc. +46 (0)46 280 18 00

Augenklinik Universitätzmedizin Charité Recruiting
Berlin, Germany, 12200
Contact: Nicole Stübiger, Prof Dr         
Universitätsklinikum Düsseldorf Recruiting
Düsseldorf, Germany, 40225
Contact: Gerd Geerling, Prof MD         
Universitäts-Augenklinik Freiburg Recruiting
Freiburg, Germany, 79106
Contact: Chris Böhringer, Prof Dr         
Augenklinik Köln, Merheim Recruiting
Köln, Germany, 51109
Contact: Stefan Christmann, Dr         
Universitäts-klinikum Schleswig-Holstein Recruiting
Lübeck, Germany, 23538
Contact: Anne Brüggemann, Dr med         
Augenklinik, Universitätsklinikum Tübingen Recruiting
Tübingen, Germany, 72026
Contact: Christoph Deuter, Dr. med         
Universitäts-Augenklinik Recruiting
Würzburg, Germany, 97080
Contact: Daniel Kampik, Dr med         
St Eriks Eye Hospital Recruiting
Stockholm, Sweden
Contact: Carl Gustaf Laurell, MD PhD         
Sponsors and Collaborators
Adenovir Pharma AB
TFS Trial Form Support AB
Principal Investigator: Carl Gustaf Laurell, MD PhD St Eriks Eye Hospital
  More Information

No publications provided

Responsible Party: Adenovir Pharma AB Identifier: NCT01977443     History of Changes
Other Study ID Numbers: 2012/ADE002, 2012-005694-31
Study First Received: October 31, 2013
Last Updated: April 30, 2015
Health Authority: Sweden: Medical Products Agency
Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Eye Infections
Eye Infections, Viral
Conjunctivitis, Viral
Conjunctival Diseases
Corneal Diseases
Eye Diseases
Virus Diseases
Ophthalmic Solutions
Autonomic Agents
Cardiovascular Agents
Nasal Decongestants
Peripheral Nervous System Agents
Pharmaceutical Solutions
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses
Vasoconstrictor Agents processed this record on November 25, 2015